D. Welsch

发表

Carbohydrate-linked asparagine-101 of prothrombin contains a metal ion protected acetylation site. Acetylation of this site causes loss of metal ion induced protein fluorescence change.

G. Nelsestuen, D. Welsch, 1988, Biochemistry.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Manish R. Patel, R. Sullivan, K. Flaherty, 2017, Cancer discovery.

The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.

X. Hu, Suzhen Li, Chunsheng Xia, 2005, Molecular endocrinology.

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

R. Sullivan, P. Sager, F. Janku, 2018, Cancer Chemotherapy and Pharmacology.

Molecular cloning and expression of human leukotriene C4 synthase.

P. Isakson, S. Hauser, D. Creely, 1994, Advances in prostaglandin, thromboxane, and leukotriene research.

Novel, selective Δ6 or Δ5 fatty acid desaturase inhibitors as antiinflammatory agents in mice

K. Duffin, P. Needleman, A. Raz, 2007, Lipids.

Lipid remodeling in mouse liver and plasma resulting from Δ6 fatty acid desaturase inhibition

K. Duffin, P. Needleman, A. Raz, 2001, Lipids.

Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice.

K. Duffin, P. Needleman, A. Raz, 1999, Lipids.

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

Hyo Song Kim, F. Janku, J. Cheong, 2022, Investigational New Drugs.

Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis

R. Willette, P. Mangrolia, D. Welsch, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

D. Rohrer, C. Carron, C. Wegner, 2010, ACS medicinal chemistry letters.

Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice.

K. Duffin, P. Needleman, A. Raz, 1998, The Journal of pharmacology and experimental therapeutics.

Molecular cloning and expression of human leukotriene-C4 synthase.

P. Isakson, S. Hauser, D. Creely, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of 1-(2-deoxy-2-fluoro-1-d-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

C. Bettegowda, S. Saha, G. Decrescenzo, 2014, World journal of microbiology & biotechnology.

Evaluation of 1-(2-deoxy-2-fluoro-1-d-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

C. Bettegowda, S. Saha, G. Decrescenzo, 2014, World Journal of Microbiology and Biotechnology.

Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa.

D. Welsch, K. Day, 1992, Thrombosis research.

Metalloproteases and inhibitors in arthritic diseases.

J. Pelletier, J. Martel-Pelletier, J. Pelletier, 2001, Best practice & research. Clinical rheumatology.

Comparison of Recombinant Tissue Factor Pathway Inhibitors Expressed in Human SK Hepatoma, Mouse C127, Baby Hamster Kidney, and Chinese Hamster Ovary Cells

W. Novotny, R. Leimgruber, G. Broze, 1992, Thrombosis and Haemostasis.

Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.

T. Wun, D. Welsch, W. Novotny, 1991, Thrombosis research.

Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.

O. Nemirovskiy, T. Sunyer, D. Dufield, 2007, Analytical biochemistry.

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

D. Dimitrov, S. Seaman, C. Szot, 2017, Cancer cell.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Nicholas D. Camarda, Jeffrey W. Miller, W. Hahn, 2018, Cancer discovery.

Tumor stroma‐targeted antibody‐drug conjugate triggers localized anticancer drug release

D. Dimitrov, S. Seaman, C. Szot, 2018, The Journal of clinical investigation.

Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.

W. Stallings, A. Stevens, J. McDonald, 2002, Biochimica et biophysica acta.

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

R. Sullivan, J. Wu, M. Lacouture, 2021, Investigational New Drugs.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Paul Shapiro, Alex M Aronov, Mark Namchuk, 2017, Molecular Cancer Therapeutics.

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Ying Yu, Gary A Decrescenzo, James R Kiefer, 2010, Journal of medicinal chemistry.

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.

R. Sullivan, K. Flaherty, J. Sosman, 2017 .

Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

J. Roix, M. Garnett, C. Benes, 2015 .

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.

R. Sullivan, K. Flaherty, J. Sosman, 2015 .

Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells.

S. W. Lin, K. Smith, D. Stafford, 1990, The Journal of biological chemistry.

Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis.

R. Buck, K. Brandt, S. Mazzuca, 2006, Osteoarthritis and cartilage.

Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1.

G. Nelsestuen, G L Nelsestuen, D J Welsch, 1988, Biochemistry.

Molecular Defect (Gla+14 +Lys) and Its Functional Consequences in a Hereditary Factor X Deficiency (Factor X “Vorarlberg”)*

S. Reddy, P. Jagadeeswaran, K. High, 2001 .

Anti-CD 276-drug conjugates display potent anti-tumor and anti-metastatic activity d Pyrrolobenzodiazepine dimers are optimal warheads for targeting tumor

D. Dimitrov, S. Seaman, C. Szot, 2022 .

Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli.

R. Leimgruber, B. Foy, T. Wun, 1994, Protein expression and purification.

Partial purification and characterization of bovine liver aspartyl beta-hydroxylase.

V. Garsky, A. Stern, M. Sardana, 1990, The Journal of biological chemistry.

Chemical modification of prothrombin fragment 1: documentation of sequential, two-stage loss of protein function.

G. Nelsestuen, D. Welsch, C. Pletcher, 1988, Biochemistry.

Irreversible degradation of histidine-96 of prothrombin fragment 1 during protein acetylation: another unusually reactive site in the kringle.

G. Nelsestuen, D. Welsch, 1988, Biochemistry.

Modulation of adjuvant-induced arthritis by dietary arachidonic acid in essential fatty acid-deficient rats

A. Raz, D. Welsch, M. Obukowicz, 1997, Lipids.

Anticorps anti-cd276 (b7h3)

D. Dimitrov, S. Seaman, S. Saha, 2015 .

Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells.

D. Welsch, S. Lin, K. J. Smith, 1990, The Journal of biological chemistry.

Molecular cloning and expression of human leukotriene-C 4 synthase

P. Isakson, S. Hauser, D. Creely, 2022 .